Xu N, Jiang L, Xu L, et al. - Among patients with 3-vessel disease (TVD) managed with the following treatment options, including medical therapy alone, percutaneous coronary intervention, and coronary artery bypass grafting, researchers examined the link between plasma lipoprotein(a) [Lp(a)] and long-term clinical outcomes. They analyzed consecutive patients (n = 6,175) with angiographically proved TVD and available baseline Lp(a) data. Two sub-groups were defined on the basis of median level of Lp(a) at admission. Major adverse cardiovascular events (MACE), including all-cause death, myocardial infarction and unplanned revascularization, were considered as the primary endpoint. All patients were observed for a median duration of 6.2 years. They noted that the high Lp (a) and low Lp (a) groups were 24.3% to 22.1%, respectively, for MACE incidence. After risk factors were adjusted, high Lp(a) levels was identified as an independent predictor of primary outcome. Findings are suggestive of the potential of plasma Lp(a) as a biomarker for risk stratification as well as prognosis in patients with a diagnosis of TVD.